

1-1 By: Klick, Morales of Maverick H.B. No. 3286
 1-2 (Senate Sponsor - Kolkhorst)
 1-3 (In the Senate - Received from the House May 8, 2023;
 1-4 May 9, 2023, read first time and referred to Committee on Health &
 1-5 Human Services; May 18, 2023, reported favorably by the following
 1-6 vote: Yeas 8, Nays 0; May 18, 2023, sent to printer.)

1-7 COMMITTEE VOTE

	Yea	Nay	Absent	PNV
1-8				
1-9	X			
1-10	X			
1-11	X			
1-12	X			
1-13			X	
1-14	X			
1-15	X			
1-16	X			
1-17	X			

1-18 A BILL TO BE ENTITLED
 1-19 AN ACT

1-20 relating to prescription drug benefits under Medicaid and the child
 1-21 health plan program.

1-22 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:

1-23 SECTION 1. Subchapter B, Chapter 531, Government Code, is
 1-24 amended by adding Section 531.0691 to read as follows:

1-25 Sec. 531.0691. VENDOR DRUG PROGRAM INCLUSION. The
 1-26 commission shall ensure that the vendor drug program includes all
 1-27 drugs and national drug codes made available on the federal
 1-28 Medicaid Drug Rebate Program regardless of the status of the
 1-29 certification of information for the drug.

1-30 SECTION 2. Chapter 533, Government Code, is amended by
 1-31 adding Subchapter C to read as follows:

1-32 SUBCHAPTER C. PRESCRIPTION DRUG BENEFITS UNDER CERTAIN OUTPATIENT
 1-33 PHARMACY BENEFIT PLANS

1-34 Sec. 533.071. PREFERRED DRUG LIST EXCEPTIONS. (a) The
 1-35 commission shall adopt rules allowing exceptions to the preferred
 1-36 drug list if:

1-37 (1) the drug required under the preferred drug list:

1-38 (A) is contraindicated;

1-39 (B) will likely cause an adverse reaction in or
 1-40 physical or mental harm to the recipient; or

1-41 (C) is expected to be ineffective based on the
 1-42 known clinical characteristics of the recipient and the known
 1-43 characteristics of the prescription drug regimen;

1-44 (2) the recipient previously discontinued taking the
 1-45 preferred drug at any point in the recipient's clinical history and
 1-46 for any length of time because the drug:

1-47 (A) was not effective;

1-48 (B) had a diminished effect; or

1-49 (C) resulted in an adverse event;

1-50 (3) the recipient was prescribed and is taking a
 1-51 nonpreferred drug in the antidepressant or antipsychotic drug class
 1-52 and the recipient:

1-53 (A) was prescribed the nonpreferred drug before
 1-54 being discharged from an inpatient facility;

1-55 (B) is stable on the nonpreferred drug; and

1-56 (C) is at risk of experiencing complications from
 1-57 switching from the nonpreferred drug to another drug; or

1-58 (4) the preferred drug is not available for reasons
 1-59 outside of the Medicaid managed care organization's control,
 1-60 including because:

1-61 (A) the drug is in short supply according to the

2-1 Food and Drug Administration Drug Shortages Database; or
 2-2 (B) the drug's manufacturer has placed the drug
 2-3 on backorder or allocation.

2-4 (b) An exception provided under this section does not
 2-5 subject the Medicaid managed care plan to liquidated damages for
 2-6 failing to comply with the preferred drug list.

2-7 SECTION 3. Section 531.072, Government Code, is amended by
 2-8 adding Subsections (b-3), (g), and (h) to read as follows:

2-9 (b-3) Notwithstanding Subsection (b), the preferred drug
 2-10 lists must contain all therapeutic equivalents for a generic drug
 2-11 on the preferred drug list.

2-12 (g) The commission shall develop an expedited review
 2-13 process to consider requests from managed care organizations and
 2-14 providers to add drugs to the preferred drug list.

2-15 (h) The commission shall grant temporary non-preferred
 2-16 status to new drugs that are available but have not yet been
 2-17 reviewed by the drug utilization review board and establish
 2-18 criteria for authorizing drugs with temporary non-preferred
 2-19 status.

2-20 SECTION 4. Section 531.073(b), Government Code, is amended
 2-21 to read as follows:

2-22 (b) The commission shall establish procedures for the prior
 2-23 authorization requirement under the Medicaid vendor drug program to
 2-24 ensure that the requirements of 42 U.S.C. Section 1396r-8(d)(5) and
 2-25 its subsequent amendments are met. Specifically, the procedures
 2-26 must ensure that:

2-27 (1) ~~[a prior authorization requirement is not imposed~~
 2-28 ~~for a drug before the drug has been considered at a meeting of the~~
 2-29 ~~Drug Utilization Review Board under Section 531.0736;~~

2-30 ~~[(2)]~~ there will be a response to a request for prior
 2-31 authorization by telephone or other telecommunications device
 2-32 within 24 hours after receipt of a request for prior authorization;
 2-33 and

2-34 (2) ~~[(3)]~~ a 72-hour supply of the drug prescribed will
 2-35 be provided in an emergency or if the commission does not provide a
 2-36 response within the time required by Subdivision (1) ~~[(2)]~~.

2-37 SECTION 5. Sections 531.0736(c) and (d), Government Code,
 2-38 are amended to read as follows:

2-39 (c) The executive commissioner shall determine the
 2-40 composition of the board, which must:

2-41 (1) comply with applicable federal law, including 42
 2-42 C.F.R. Section 456.716;

2-43 (2) include three ~~[two]~~ representatives of managed
 2-44 care organizations ~~[as nonvoting members]~~, all ~~[one]~~ of whom must
 2-45 be physicians or pharmacists ~~[a physician and one of whom must be a~~
 2-46 ~~pharmacist]~~;

2-47 (3) include at least 17 physicians and pharmacists
 2-48 who:

2-49 (A) provide services across the entire
 2-50 population of Medicaid recipients and represent different
 2-51 specialties, including at least one of each of the following types
 2-52 of physicians:

2-53 (i) a pediatrician;
 2-54 (ii) a primary care physician;
 2-55 (iii) an obstetrician and gynecologist;
 2-56 (iv) a child and adolescent psychiatrist;

2-57 and

2-58 (v) an adult psychiatrist; and

2-59 (B) have experience in either developing or
 2-60 practicing under a preferred drug list; and

2-61 (4) include a consumer advocate who represents
 2-62 Medicaid recipients.

2-63 (d) Notwithstanding any other law, members ~~[Members]~~
 2-64 appointed under Subsection (c)(2) may attend quarterly and other
 2-65 regularly scheduled meetings, but may not:

2-66 (1) attend portions of the executive sessions in which
 2-67 confidential drug pricing information is shared; or

2-68 (2) access confidential drug pricing information.

2-69 SECTION 6. If before implementing any provision of this Act

3-1 a state agency determines that a waiver or authorization from a
3-2 federal agency is necessary for implementation of that provision,
3-3 the agency affected by the provision shall request the waiver or
3-4 authorization and may delay implementing that provision until the
3-5 waiver or authorization is granted.

3-6 SECTION 7. This Act takes effect September 1, 2023.

3-7

* * * * *